Joel M Gelfand Highlights Platelet RNA Signature in Psoriasis
Joel M Gelfand, Director Center for Clinical Sciences in Dermatology at University of Pennsylvania School of Medicine, shared a post on LinkedIn:
“An under investigated topic in psoriasis is its impact on platelets. Here, Michael Garshick demonstrates that even when psoriasis is well controlled with biologics platelets remain activated and have a newly discovered RNA signature that predicts future cardiovascular events.
Details here
Álvaro González Cantero has also recently demonstrated that patients with well controlled psoriasis have residual systemic inflammation
Details here
These findings provide more evidence that simply treating the skin may not be enough to lower CV risk and that more holistic multi-pronged approaches are needed. Note, I am a collaborator and author on both papers”
Stay updated with Hemostasis Today.
-
Aug 20, 2026, 06:15Muhammad Umair Mushtaq: Outcomes of Matched Sibling Versus Haploidentical Transplantation
-
Aug 20, 2026, 06:03Access to Bleeding Disorder Treatment Shouldn’t Depend on Where You Live – WFH
-
Aug 20, 2026, 04:42Chris Zahner: Why Healthy People Can Have Abnormal Lab Results
-
Aug 20, 2026, 03:57Reza Shojaei: What the First U.S. Freeze-Dried Plasma Approval Means
-
Aug 20, 2026, 01:23Jessica Erley: Understanding Patient Experience Beyond the Clinical Encounter
-
Aug 20, 2026, 01:19Dries De Wolf: Innovative Gene Therapy for Hemophilia B
-
Aug 19, 2026, 19:09Gregory Lip: PFO Closure in Younger Patients With Cryptogenic Stroke
-
Aug 19, 2026, 18:51Filippo Crea: AF and Alzheimer’s Disease – Does the Anticoagulant Choice Matter for the Brain?
-
Aug 19, 2026, 18:42Alan Nurden: How Procoagulant Platelets Relate to Microparticle Release?